Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy and lower costs in younger patients, and slightly increased use of chemotherapy and higher costs in older patients. Genomic testing in actual practice may "rule out" chemotherapy in younger women, and "rule in" chemotherapy in older women.
L D I R E S E A R C H B R I E F
Among women older than 75, however, RS testing increased chemotherapy use by almost 6 percentage points (from 8.7% to 14.4%) and increased medical spending by more than $3,000 (from $29,720 to $33,209) . The authors found that the rate of RS testing decreased with age after 55.
THE QUESTION
The promise of personalized genomic testing is that it can reduce unnecessary care and costs by predicting which patients are most likely to benefit from a treatment. After surgery, women with early-stage breast cancer face the decision of whether to undergo expensive and potentially toxic chemotherapy to prevent recurrence, although most will not have a recurrence. The 21-gene recurrence score test (RS) was developed in 2004 to predict this risk, and its use in clinical medicine is increasing. In this study of actual treatment patterns, LDI Senior Fellows Andrew Epstein and Peter Groeneveld and colleagues investigate how genomic testing of women with earlystage breast cancer affects subsequent chemotherapy use and medical spending in the year after diagnosis.
THE FINDINGS
The study found that RS testing influenced treatment decisions and medical expenses differently for younger and older patients. Among women younger than 55, RS testing was associated with a nearly 20 percentage point decrease in use of chemotherapy (from 60.8% to 41.5%) and $15,000 less in medical spending in the 12 months after diagnosis (from $96,667 to $81,334).
Incremental effect of RS receipt on probability of receiving chemotherapy and on total spending
The gold lines represent the difference in probability (0 to 1 scale) of chemotherapy use among RS recipients. The blue lines represent the change in total health care costs (2010 $US) among RS recipients. The vertical lines indicate 95% CIs for the point estimates. 
